#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-9	Polygenic	_
1-2	10-14	Risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
1-3	15-20	Score	_
1-4	21-24	for	_
1-5	25-38	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-6	39-42	and	_
1-7	43-58	Face-Processing	http://maven.renci.org/NeuroBridge/neurobridge#AffectiveProcessingScale
1-8	59-66	Network	http://maven.renci.org/NeuroBridge/neurobridge#AffectiveProcessingScale
1-9	67-69	in	_
1-10	70-75	Young	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
1-11	76-85	Adulthood	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
1-12	86-94	Abstract	_
1-13	95-106	Development	_
1-14	107-109	of	_
1-15	110-123	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-16	124-131	relates	_
1-17	132-134	to	_
1-18	135-139	both	_
1-19	140-147	genetic	_
1-20	148-151	and	_
1-21	152-165	environmental	_
1-22	166-173	factors	_
1-23	174-175	.	_

2-1	176-186	Functional	_
2-2	187-195	deficits	_
2-3	196-198	in	_
2-4	199-203	many	_
2-5	204-213	cognitive	_
2-6	214-221	domains	_
2-7	222-223	,	_
2-8	224-233	including	_
2-9	234-237	the	_
2-10	238-245	ability	_
2-11	246-248	to	_
2-12	249-260	communicate	_
2-13	261-263	in	_
2-14	264-270	social	_
2-15	271-283	interactions	_
2-16	284-287	and	_
2-17	288-296	impaired	_
2-18	297-308	recognition	_
2-19	309-311	of	_
2-20	312-318	facial	_
2-21	319-330	expressions	_
2-22	331-332	,	_
2-23	333-336	are	_
2-24	337-343	common	_
2-25	344-347	for	_
2-26	348-356	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-27	357-361	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-28	362-375	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-29	376-379	and	_
2-30	380-385	might	_
2-31	386-390	also	_
2-32	391-393	be	_
2-33	394-401	present	_
2-34	402-404	in	_
2-35	405-416	individuals	_
2-36	417-419	at	_
2-37	420-424	risk	_
2-38	425-427	of	_
2-39	428-438	developing	_
2-40	439-452	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-41	453-454	.	_

3-1	455-459	Here	_
3-2	460-462	we	_
3-3	463-470	explore	_
3-4	471-478	whether	_
3-5	479-481	an	_
3-6	482-492	individual	_
3-7	493-494	’	_
3-8	495-496	s	_
3-9	497-506	polygenic	_
3-10	507-511	risk	_
3-11	512-517	score	_
3-12	518-519	(	_
3-13	520-523	PRS	_
3-14	524-525	)	_
3-15	526-529	for	_
3-16	530-543	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-17	544-546	is	_
3-18	547-557	associated	_
3-19	558-562	with	_
3-20	563-566	the	_
3-21	567-573	degree	_
3-22	574-576	of	_
3-23	577-590	interregional	_
3-24	591-603	similarities	_
3-25	604-606	in	_
3-26	607-612	blood	_
3-27	613-619	oxygen	_
3-28	620-635	level–dependent	_
3-29	636-637	(	_
3-30	638-642	BOLD	_
3-31	643-644	)	_
3-32	645-651	signal	_
3-33	652-655	and	_
3-34	656-660	gray	_
3-35	661-667	matter	_
3-36	668-674	volume	_
3-37	675-677	of	_
3-38	678-681	the	_
3-39	682-697	face-processing	_
3-40	698-705	network	_
3-41	706-709	and	_
3-42	710-717	whether	_
3-43	718-721	the	_
3-44	722-730	exposure	_
3-45	731-733	to	_
3-46	734-739	early	_
3-47	740-749	adversity	_
3-48	750-759	moderates	_
3-49	760-764	this	_
3-50	765-776	association	_
3-51	777-778	.	_

4-1	779-780	A	_
4-2	781-786	total	_
4-3	787-789	of	_
4-4	790-792	90	_
4-5	793-804	individuals	_
4-6	805-806	(	_
4-7	807-811	mean	_
4-8	812-815	age	_
4-9	816-818	22	_
4-10	819-824	years	_
4-11	825-826	,	_
4-12	827-831	both	_
4-13	832-842	functional	_
4-14	843-846	and	_
4-15	847-857	structural	_
4-16	858-862	data	_
4-17	863-872	available	_
4-18	873-874	)	_
4-19	875-879	were	_
4-20	880-884	used	_
4-21	885-888	for	_
4-22	889-898	discovery	_
4-23	899-907	analyses	_
4-24	908-909	,	_
4-25	910-913	and	_
4-26	914-917	211	_
4-27	918-929	individuals	_
4-28	930-931	(	_
4-29	932-936	mean	_
4-30	937-940	age	_
4-31	941-943	26	_
4-32	944-949	years	_
4-33	950-951	,	_
4-34	952-962	structural	_
4-35	963-967	data	_
4-36	968-977	available	_
4-37	978-979	)	_
4-38	980-984	were	_
4-39	985-989	used	_
4-40	990-993	for	_
4-41	994-1005	replication	_
4-42	1006-1008	of	_
4-43	1009-1012	the	_
4-44	1013-1023	structural	_
4-45	1024-1032	findings	_
4-46	1033-1034	.	_

5-1	1035-1039	Both	_
5-2	1040-1047	samples	_
5-3	1048-1052	were	_
5-4	1053-1058	drawn	_
5-5	1059-1063	from	_
5-6	1064-1067	the	_
5-7	1068-1076	Northern	_
5-8	1077-1084	Finland	_
5-9	1085-1090	Birth	_
5-10	1091-1097	Cohort	_
5-11	1098-1102	1986	_
5-12	1103-1104	.	_

6-1	1105-1107	We	_
6-2	1108-1113	found	_
6-3	1114-1118	that	_
6-4	1119-1122	the	_
6-5	1123-1129	degree	_
6-6	1130-1132	of	_
6-7	1133-1146	interregional	_
6-8	1147-1159	similarities	_
6-9	1160-1162	in	_
6-10	1163-1167	BOLD	_
6-11	1168-1174	signal	_
6-12	1175-1178	and	_
6-13	1179-1183	gray	_
6-14	1184-1190	matter	_
6-15	1191-1197	volume	_
6-16	1198-1202	vary	_
6-17	1203-1205	as	_
6-18	1206-1207	a	_
6-19	1208-1216	function	_
6-20	1217-1219	of	_
6-21	1220-1223	PRS	_
6-22	1224-1225	;	_
6-23	1226-1232	lowest	_
6-24	1233-1246	interregional	_
6-25	1247-1258	correlation	_
6-26	1259-1260	(	_
6-27	1261-1265	both	_
6-28	1266-1274	measures	_
6-29	1275-1276	)	_
6-30	1277-1280	was	_
6-31	1281-1289	observed	_
6-32	1290-1292	in	_
6-33	1293-1304	individuals	_
6-34	1305-1309	with	_
6-35	1310-1314	high	_
6-36	1315-1318	PRS	_
6-37	1319-1320	.	_

7-1	1321-1323	We	_
7-2	1324-1328	also	_
7-3	1329-1339	replicated	_
7-4	1340-1343	the	_
7-5	1344-1348	gray	_
7-6	1349-1355	matter	_
7-7	1356-1362	volume	_
7-8	1363-1370	finding	_
7-9	1371-1372	.	_

8-1	1373-1375	We	_
8-2	1376-1379	did	_
8-3	1380-1383	not	_
8-4	1384-1388	find	_
8-5	1389-1397	evidence	_
8-6	1398-1401	for	_
8-7	1402-1404	an	_
8-8	1405-1416	interaction	_
8-9	1417-1424	between	_
8-10	1425-1430	early	_
8-11	1431-1440	adversity	_
8-12	1441-1444	and	_
8-13	1445-1448	PRS	_
8-14	1449-1451	on	_
8-15	1452-1455	the	_
8-16	1456-1469	interregional	_
8-17	1470-1481	correlation	_
8-18	1482-1484	of	_
8-19	1485-1489	BOLD	_
8-20	1490-1496	signal	_
8-21	1497-1500	and	_
8-22	1501-1505	gray	_
8-23	1506-1512	matter	_
8-24	1513-1519	volume	_
8-25	1520-1521	.	_

9-1	1522-1524	We	_
9-2	1525-1534	speculate	_
9-3	1535-1539	that	_
9-4	1540-1543	the	_
9-5	1544-1552	observed	_
9-6	1553-1558	group	_
9-7	1559-1570	differences	_
9-8	1571-1573	in	_
9-9	1574-1585	PRS-related	_
9-10	1586-1598	correlations	_
9-11	1599-1601	in	_
9-12	1602-1606	both	_
9-13	1607-1617	modalities	_
9-14	1618-1621	may	_
9-15	1622-1628	result	_
9-16	1629-1633	from	_
9-17	1634-1645	differences	_
9-18	1646-1648	in	_
9-19	1649-1652	the	_
9-20	1653-1663	concurrent	_
9-21	1664-1674	functional	_
9-22	1675-1685	engagement	_
9-23	1686-1688	of	_
9-24	1689-1692	the	_
9-25	1693-1708	face-processing	_
9-26	1709-1716	regions	_
9-27	1717-1721	over	_
9-28	1722-1726	time	_
9-29	1727-1728	,	_
9-30	1729-1731	eg	_
9-31	1732-1733	,	_
9-32	1734-1737	via	_
9-33	1738-1749	differences	_
9-34	1750-1752	in	_
9-35	1753-1761	exposure	_
9-36	1762-1764	to	_
9-37	1765-1771	social	_
9-38	1772-1783	interaction	_
9-39	1784-1788	with	_
9-40	1789-1794	other	_
9-41	1795-1801	people	_
9-42	1802-1803	.	_

10-1	1804-1813	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	1814-1817	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	1818-1825	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	1826-1838	Participants	_
10-5	1839-1851	Participants	_
10-6	1852-1856	were	_
10-7	1857-1861	born	_
10-8	1862-1869	between	_
10-9	1870-1874	July	_
10-10	1875-1876	1	_
10-11	1877-1878	,	_
10-12	1879-1883	1985	_
10-13	1884-1885	,	_
10-14	1886-1889	and	_
10-15	1890-1894	June	_
10-16	1895-1897	30	_
10-17	1898-1899	,	_
10-18	1900-1904	1986	_
10-19	1905-1906	,	_
10-20	1907-1909	in	_
10-21	1910-1913	the	_
10-22	1914-1922	Northern	_
10-23	1923-1930	Finland	_
10-24	1931-1940	provinces	_
10-25	1941-1942	.	_

11-1	1943-1946	The	_
11-2	1947-1952	local	_
11-3	1953-1960	ethical	_
11-4	1961-1970	committee	_
11-5	1971-1979	approved	_
11-6	1980-1983	the	_
11-7	1984-1989	study	_
11-8	1990-1991	.	_

12-1	1992-1996	GWAS	_
12-2	1997-2001	data	_
12-3	2002-2004	in	_
12-4	2005-2008	the	_
12-5	2009-2013	NFBC	_
12-6	2014-2018	1986	_
12-7	2019-2029	originates	_
12-8	2030-2034	from	_
12-9	2035-2038	the	_
12-10	2039-2044	visit	_
12-11	2045-2054	conducted	_
12-12	2055-2062	between	_
12-13	2063-2069	August	_
12-14	2070-2074	2001	_
12-15	2075-2078	and	_
12-16	2079-2083	June	_
12-17	2084-2088	2002	_
12-18	2089-2090	(	_
12-19	2091-2092	N	_
12-20	2093-2094	=	_
12-21	2095-2099	3743	_
12-22	2100-2102	in	_
12-23	2103-2106	the	_
12-24	2107-2112	final	_
12-25	2113-2119	sample	_
12-26	2120-2121	)	_
12-27	2122-2123	.	_

13-1	2124-2129	Using	_
13-2	2130-2134	this	_
13-3	2135-2141	sample	_
13-4	2142-2143	,	_
13-5	2144-2146	we	_
13-6	2147-2155	explored	_
13-7	2156-2163	whether	_
13-8	2164-2167	PRS	_
13-9	2168-2175	relates	_
13-10	2176-2178	to	_
13-11	2179-2189	later-life	_
13-12	2190-2203	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-13	2204-2213	diagnosis	_
13-14	2214-2215	.	_

14-1	2216-2219	The	_
14-2	2220-2234	register-based	_
14-3	2235-2246	information	_
14-4	2247-2252	about	_
14-5	2253-2256	the	_
14-6	2257-2267	individual	_
14-7	2268-2269	’	_
14-8	2270-2271	s	_
14-9	2272-2282	later-life	_
14-10	2283-2296	schizophrenia	_
14-11	2297-2298	(	_
14-12	2299-2307	followed	_
14-13	2308-2313	until	_
14-14	2314-2318	2016	_
14-15	2319-2320	)	_
14-16	2321-2324	was	_
14-17	2325-2331	formed	_
14-18	2332-2334	by	_
14-19	2335-2340	using	_
14-20	2341-2344	the	_
14-21	2345-2354	following	_
14-22	2355-2366	nation-wide	_
14-23	2367-2375	registry	_
14-24	2376-2377	:	_
14-25	2378-2382	Care	_
14-26	2383-2391	Register	_
14-27	2392-2395	for	_
14-28	2396-2402	Health	_
14-29	2403-2407	Care	_
14-30	2408-2409	,	_
14-31	2410-2417	Finnish	_
14-32	2418-2424	Centre	_
14-33	2425-2428	for	_
14-34	2429-2437	Pensions	_
14-35	2438-2439	,	_
14-36	2440-2443	and	_
14-37	2444-2447	the	_
14-38	2448-2457	registers	_
14-39	2458-2460	of	_
14-40	2461-2464	the	_
14-41	2465-2473	National	_
14-42	2474-2480	Social	_
14-43	2481-2490	Insurance	_
14-44	2491-2500	Institute	_
14-45	2501-2502	.	_

15-1	2503-2505	We	_
15-2	2506-2510	used	_
15-3	2511-2515	both	_
15-4	2516-2517	“	_
15-5	2518-2523	broad	_
15-6	2524-2525	”	_
15-7	2526-2527	(	_
15-8	2528-2541	International	_
15-9	2542-2556	Classification	_
15-10	2557-2559	of	_
15-11	2560-2568	Diseases	_
15-12	2569-2570	,	_
15-13	2571-2576	Tenth	_
15-14	2577-2585	Revision	_
15-15	2586-2587	[	_
15-16	2588-2594	ICD-10	_
15-17	2595-2596	]	_
15-18	2597-2598	:	_
15-19	2599-2602	F20	_
15-20	2603-2604	,	_
15-21	2605-2608	F22	_
15-22	2609-2610	,	_
15-23	2611-2614	F24	_
15-24	2615-2616	,	_
15-25	2617-2620	and	_
15-26	2621-2624	F25	_
15-27	2625-2626	)	_
15-28	2627-2630	and	_
15-29	2631-2632	“	_
15-30	2633-2639	narrow	_
15-31	2640-2641	”	_
15-32	2642-2643	(	_
15-33	2644-2650	ICD-10	_
15-34	2651-2652	:	_
15-35	2653-2656	F20	_
15-36	2657-2658	)	_
15-37	2659-2669	definition	_
15-38	2670-2672	of	_
15-39	2673-2686	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-40	2687-2688	.	_

16-1	2689-2693	Next	_
16-2	2694-2695	,	_
16-3	2696-2699	two	_
16-4	2700-2704	NFBC	_
16-5	2705-2709	1986	_
16-6	2710-2720	subsamples	_
16-7	2721-2722	(	_
16-8	2723-2731	referred	_
16-9	2732-2734	to	_
16-10	2735-2737	as	_
16-11	2738-2750	neuroimaging	_
16-12	2751-2761	subsamples	_
16-13	2762-2773	hereinafter	_
16-14	2774-2775	)	_
16-15	2776-2780	were	_
16-16	2781-2785	used	_
16-17	2786-2789	for	_
16-18	2790-2799	discovery	_
16-19	2800-2803	and	_
16-20	2804-2815	replication	_
16-21	2816-2824	analyses	_
16-22	2825-2826	.	_

17-1	2827-2832	These	_
17-2	2833-2843	subsamples	_
17-3	2844-2847	are	_
17-4	2848-2857	described	_
17-5	2858-2860	in	_
17-6	2861-2867	detail	_
17-7	2868-2870	in	_
17-8	2871-2874	the	_
17-9	2875-2888	supplementary	_
17-10	2889-2897	material	_
17-11	2898-2899	.	_

18-1	2900-2907	Briefly	_
18-2	2908-2909	,	_
18-3	2910-2913	the	_
18-4	2914-2923	discovery	_
18-5	2924-2930	sample	_
18-6	2931-2932	(	_
18-7	2933-2934	N	_
18-8	2935-2936	=	_
18-9	2937-2939	90	_
18-10	2940-2941	)	_
18-11	2942-2945	was	_
18-12	2946-2955	collected	_
18-13	2956-2963	between	_
18-14	2964-2968	2007	_
18-15	2969-2972	and	_
18-16	2973-2977	2010	_
18-17	2978-2980	to	_
18-18	2981-2992	investigate	_
18-19	2993-2996	the	_
18-20	2997-3001	risk	_
18-21	3002-3004	of	_
18-22	3005-3014	psychosis	_
18-23	3015-3018	and	_
18-24	3019-3022	the	_
18-25	3023-3034	replication	_
18-26	3035-3041	sample	_
18-27	3042-3043	(	_
18-28	3044-3045	N	_
18-29	3046-3047	=	_
18-30	3048-3051	211	_
18-31	3052-3053	)	_
18-32	3054-3057	was	_
18-33	3058-3066	obtained	_
18-34	3067-3074	between	_
18-35	3075-3079	2011	_
18-36	3080-3083	and	_
18-37	3084-3088	2013	_
18-38	3089-3091	to	_
18-39	3092-3099	examine	_
18-40	3100-3112	associations	_
18-41	3113-3120	between	_
18-42	3121-3129	maternal	_
18-43	3130-3137	smoking	_
18-44	3138-3144	during	_
18-45	3145-3154	pregnancy	_
18-46	3155-3158	and	_
18-47	3159-3162	the	_
18-48	3163-3172	offspring	_
18-49	3173-3174	’	_
18-50	3175-3176	s	_
18-51	3177-3182	brain	_
18-52	3183-3186	and	_
18-53	3187-3193	mental	_
18-54	3194-3200	health	_
18-55	3201-3202	.	_

19-1	3203-3212	Polygenic	_
19-2	3213-3217	Risk	_
19-3	3218-3223	Score	_
19-4	3224-3232	Detailed	_
19-5	3233-3244	information	_
19-6	3245-3247	on	_
19-7	3248-3251	the	_
19-8	3252-3262	collection	_
19-9	3263-3265	of	_
19-10	3266-3269	the	_
19-11	3270-3277	genetic	_
19-12	3278-3285	samples	_
19-13	3286-3289	and	_
19-14	3290-3297	quality	_
19-15	3298-3305	control	_
19-16	3306-3308	of	_
19-17	3309-3312	the	_
19-18	3313-3324	genome-wide	_
19-19	3325-3329	data	_
19-20	3330-3333	are	_
19-21	3334-3342	provided	_
19-22	3343-3345	in	_
19-23	3346-3349	the	_
19-24	3350-3363	supplementary	_
19-25	3364-3372	material	_
19-26	3373-3374	.	_

20-1	3375-3378	The	_
20-2	3379-3386	results	_
20-3	3387-3389	of	_
20-4	3390-3393	the	_
20-5	3394-3398	GWAS	_
20-6	3399-3401	by	_
20-7	3402-3405	the	_
20-8	3406-3419	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
20-9	3420-3427	Working	_
20-10	3428-3433	Group	_
20-11	3434-3436	of	_
20-12	3437-3440	the	_
20-13	3441-3452	Psychiatric	_
20-14	3453-3461	Genomics	_
20-15	3462-3472	Consortium	_
20-16	3473-3477	were	_
20-17	3478-3482	used	_
20-18	3483-3486	for	_
20-19	3487-3490	the	_
20-20	3491-3502	calculation	_
20-21	3503-3505	of	_
20-22	3506-3509	PRS	_
20-23	3510-3513	for	_
20-24	3514-3527	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
20-25	3528-3530	in	_
20-26	3531-3534	the	_
20-27	3535-3539	NFBC	_
20-28	3540-3544	1986	_
20-29	3545-3551	sample	_
20-30	3552-3553	(	_
20-31	3554-3555	N	_
20-32	3556-3557	=	_
20-33	3558-3562	3743	_
20-34	3563-3564	)	_
20-35	3565-3566	.	_

21-1	3567-3570	The	_
21-2	3571-3576	score	_
21-3	3577-3580	was	_
21-4	3581-3591	calculated	_
21-5	3592-3594	on	_
21-6	3595-3612	single-nucleotide	_
21-7	3613-3626	polymorphisms	_
21-8	3627-3628	(	_
21-9	3629-3633	SNPs	_
21-10	3634-3635	)	_
21-11	3636-3644	reaching	_
21-12	3645-3656	genome-wide	_
21-13	3657-3669	significance	_
21-14	3670-3671	(	_
21-15	3672-3673	P	_
21-16	3674-3675	=	_
21-17	3676-3677	5	_
21-18	3678-3679	×	_
21-19	3680-3684	10−8	_
21-20	3685-3686	)	_
21-21	3687-3688	.	_

22-1	3689-3690	A	_
22-2	3691-3696	total	_
22-3	3697-3699	of	_
22-4	3700-3703	112	_
22-5	3704-3708	SNPs	_
22-6	3709-3713	were	_
22-7	3714-3719	found	_
22-8	3720-3722	in	_
22-9	3723-3726	the	_
22-10	3727-3734	imputed	_
22-11	3735-3739	NFBC	_
22-12	3740-3744	1986	_
22-13	3745-3749	GWAS	_
22-14	3750-3757	dataset	_
22-15	3758-3759	.	_

23-1	3760-3763	For	_
23-2	3764-3768	each	_
23-3	3769-3780	participant	_
23-4	3781-3782	(	_
23-5	3783-3784	N	_
23-6	3785-3786	=	_
23-7	3787-3791	3743	_
23-8	3792-3793	)	_
23-9	3794-3795	,	_
23-10	3796-3798	we	_
23-11	3799-3809	calculated	_
23-12	3810-3813	the	_
23-13	3814-3817	sum	_
23-14	3818-3820	of	_
23-15	3821-3824	the	_
23-16	3825-3829	risk	_
23-17	3830-3834	SNPs	_
23-18	3835-3845	multiplied	_
23-19	3846-3848	by	_
23-20	3849-3852	the	_
23-21	3853-3859	effect	_
23-22	3860-3864	size	_
23-23	3865-3866	(	_
23-24	3867-3876	logarithm	_
23-25	3877-3879	of	_
23-26	3880-3883	the	_
23-27	3884-3888	odds	_
23-28	3889-3894	ratio	_
23-29	3895-3898	for	_
23-30	3899-3912	schizophrenia	_
23-31	3913-3914	)	_
23-32	3915-3916	.	_

24-1	3917-3920	PRS	_
24-2	3921-3924	was	_
24-3	3925-3933	adjusted	_
24-4	3934-3937	for	_
24-5	3938-3939	4	_
24-6	3940-3949	principal	_
24-7	3950-3960	components	_
24-8	3961-3963	to	_
24-9	3964-3971	account	_
24-10	3972-3975	for	_
24-11	3976-3986	population	_
24-12	3987-4001	stratification	_
24-13	4002-4003	.	_

25-1	4004-4006	In	_
25-2	4007-4010	the	_
25-3	4011-4023	neuroimaging	_
25-4	4024-4034	subsamples	_
25-5	4035-4036	,	_
25-6	4037-4039	we	_
25-7	4040-4044	used	_
25-8	4045-4048	the	_
25-9	4049-4055	median	_
25-10	4056-4061	split	_
25-11	4062-4064	of	_
25-12	4065-4068	PRS	_
25-13	4069-4071	to	_
25-14	4072-4078	create	_
25-15	4079-4080	“	_
25-16	4081-4085	high	_
25-17	4086-4087	”	_
25-18	4088-4091	and	_
25-19	4092-4093	“	_
25-20	4094-4097	low	_
25-21	4098-4099	”	_
25-22	4100-4103	PRS	_
25-23	4104-4110	groups	_
25-24	4111-4112	.	_

26-1	4113-4118	Early	_
26-2	4119-4128	Adversity	_
26-3	4129-4134	Early	_
26-4	4135-4146	adversities	_
26-5	4147-4149	in	_
26-6	4150-4153	the	_
26-7	4154-4166	neuroimaging	_
26-8	4167-4177	subsamples	_
26-9	4178-4182	were	_
26-10	4183-4192	evaluated	_
26-11	4193-4197	with	_
26-12	4198-4201	the	_
26-13	4202-4208	Trauma	http://maven.renci.org/NeuroBridge/neurobridge#PosttraumaticStressDisorderSymptomsScale
26-14	4209-4212	and	http://maven.renci.org/NeuroBridge/neurobridge#PosttraumaticStressDisorderSymptomsScale
26-15	4213-4221	Distress	http://maven.renci.org/NeuroBridge/neurobridge#PosttraumaticStressDisorderSymptomsScale
26-16	4222-4227	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PosttraumaticStressDisorderSymptomsScale
26-17	4228-4229	(	http://maven.renci.org/NeuroBridge/neurobridge#PosttraumaticStressDisorderSymptomsScale
26-18	4230-4234	TADS	http://maven.renci.org/NeuroBridge/neurobridge#PosttraumaticStressDisorderSymptomsScale
26-19	4235-4236	)	http://maven.renci.org/NeuroBridge/neurobridge#PosttraumaticStressDisorderSymptomsScale
26-20	4237-4238	.	_

27-1	4239-4243	TADS	_
27-2	4244-4255	self-report	_
27-3	4256-4264	contains	_
27-4	4265-4267	43	_
27-5	4268-4278	statements	_
27-6	4279-4280	,	_
27-7	4281-4283	of	_
27-8	4284-4289	which	_
27-9	4290-4292	25	_
27-10	4293-4303	statements	_
27-11	4304-4307	are	_
27-12	4308-4312	used	_
27-13	4313-4315	to	_
27-14	4316-4324	evaluate	_
27-15	4325-4338	psychological	_
27-16	4339-4346	traumas	_
27-17	4347-4348	(	_
27-18	4349-4358	emotional	_
27-19	4359-4364	abuse	_
27-20	4365-4366	,	_
27-21	4367-4375	physical	_
27-22	4376-4381	abuse	_
27-23	4382-4383	,	_
27-24	4384-4390	sexual	_
27-25	4391-4396	abuse	_
27-26	4397-4398	,	_
27-27	4399-4408	emotional	_
27-28	4409-4416	neglect	_
27-29	4417-4418	,	_
27-30	4419-4422	and	_
27-31	4423-4431	physical	_
27-32	4432-4439	neglect	_
27-33	4440-4441	)	_
27-34	4442-4443	.	_

28-1	4444-4447	All	_
28-2	4448-4458	statements	_
28-3	4459-4463	have	_
28-4	4464-4465	5	_
28-5	4466-4476	responding	_
28-6	4477-4484	options	_
28-7	4485-4491	scored	_
28-8	4492-4494	on	_
28-9	4495-4496	a	_
28-10	4497-4502	scale	_
28-11	4503-4507	from	_
28-12	4508-4509	0	_
28-13	4510-4512	to	_
28-14	4513-4514	4	_
28-15	4515-4516	:	_
28-16	4517-4522	Never	_
28-17	4523-4524	,	_
28-18	4525-4531	Rarely	_
28-19	4532-4533	,	_
28-20	4534-4543	Sometimes	_
28-21	4544-4545	,	_
28-22	4546-4551	Often	_
28-23	4552-4553	,	_
28-24	4554-4557	and	_
28-25	4558-4564	Nearly	_
28-26	4565-4571	always	_
28-27	4572-4573	.	_

29-1	4574-4578	This	_
29-2	4579-4584	study	_
29-3	4585-4589	used	_
29-4	4590-4595	total	_
29-5	4596-4600	TADS	_
29-6	4601-4607	scores	_
29-7	4608-4609	.	_

30-1	4610-4612	In	_
30-2	4613-4614	a	_
30-3	4615-4623	previous	_
30-4	4624-4629	study	_
30-5	4630-4631	,	_
30-6	4632-4635	the	_
30-7	4636-4644	internal	_
30-8	4645-4656	consistency	_
30-9	4657-4659	of	_
30-10	4660-4664	TADS	_
30-11	4665-4677	self-reports	_
30-12	4678-4681	was	_
30-13	4682-4686	0.92	_
30-14	4687-4688	(	_
30-15	4689-4697	Cronbach	_
30-16	4698-4699	’	_
30-17	4700-4701	s	_
30-18	4702-4703	α	_
30-19	4704-4705	)	_
30-20	4706-4707	,	_
30-21	4708-4711	and	_
30-22	4712-4722	intraclass	_
30-23	4723-4735	coefficients	_
30-24	4736-4739	for	_
30-25	4740-4744	TADS	_
30-26	4745-4749	were	_
30-27	4750-4754	good	_
30-28	4755-4757	to	_
30-29	4758-4767	excellent	_
30-30	4768-4772	when	_
30-31	4773-4781	compared	_
30-32	4782-4786	with	_
30-33	4787-4790	the	_
30-34	4791-4802	interviewed	_
30-35	4803-4807	TADS	_
30-36	4808-4810	as	_
30-37	4811-4812	a	_
30-38	4813-4817	gold	_
30-39	4818-4826	standard	_
30-40	4827-4828	.	_

31-1	4829-4833	TADS	_
31-2	4834-4837	has	_
31-3	4838-4842	been	_
31-4	4843-4848	shown	_
31-5	4849-4851	to	_
31-6	4852-4861	associate	_
31-7	4862-4866	with	_
31-8	4867-4877	depression	_
31-9	4878-4881	and	_
31-10	4882-4894	help-seeking	_
31-11	4895-4898	for	_
31-12	4899-4905	mental	_
31-13	4906-4914	problems	_
31-14	4915-4916	.	_

32-1	4917-4919	In	_
32-2	4920-4923	the	_
32-3	4924-4933	discovery	_
32-4	4934-4940	sample	_
32-5	4941-4942	,	_
32-6	4943-4947	TADS	http://maven.renci.org/NeuroBridge/neurobridge#Stadiometer
32-7	4948-4954	scores	_
32-8	4955-4965	correlated	_
32-9	4966-4970	with	_
32-10	4971-4974	the	_
32-11	4975-4984	prodromal	_
32-12	4985-4993	syndrome	_
32-13	4994-4996	as	_
32-14	4997-5006	diagnosed	_
32-15	5007-5011	with	_
32-16	5012-5015	the	_
32-17	5016-5020	SIPS	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
32-18	5021-5030	interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
32-19	5031-5032	.	_

33-1	5033-5044	Furthermore	_
33-2	5045-5046	,	_
33-3	5047-5051	TADS	http://maven.renci.org/NeuroBridge/neurobridge#Stadiometer
33-4	5052-5058	scores	_
33-5	5059-5063	were	_
33-6	5064-5070	higher	_
33-7	5071-5073	in	_
33-8	5074-5085	individuals	_
33-9	5086-5093	exposed	_
33-10	5094-5095	(	_
33-11	5096-5098	vs	_
33-12	5099-5109	nonexposed	_
33-13	5110-5111	)	_
33-14	5112-5114	to	_
33-15	5115-5123	maternal	_
33-16	5124-5133	cigarette	_
33-17	5134-5141	smoking	_
33-18	5142-5148	during	_
33-19	5149-5158	pregnancy	_
33-20	5159-5160	(	_
33-21	5161-5172	replication	_
33-22	5173-5179	sample	_
33-23	5180-5181	)	_
33-24	5182-5183	.	_

34-1	5184-5187	For	_
34-2	5188-5192	this	_
34-3	5193-5199	reason	_
34-4	5200-5201	,	_
34-5	5202-5206	TADS	_
34-6	5207-5213	scores	_
34-7	5214-5218	were	_
34-8	5219-5227	adjusted	_
34-9	5228-5231	for	_
34-10	5232-5235	the	_
34-11	5236-5245	prodromal	_
34-12	5246-5254	syndrome	_
34-13	5255-5256	(	_
34-14	5257-5266	discovery	_
34-15	5267-5273	sample	_
34-16	5274-5275	)	_
34-17	5276-5279	and	_
34-18	5280-5288	maternal	_
34-19	5289-5296	smoking	_
34-20	5297-5303	during	_
34-21	5304-5313	pregnancy	_
34-22	5314-5315	(	_
34-23	5316-5327	replication	_
34-24	5328-5334	sample	_
34-25	5335-5336	)	_
34-26	5337-5342	using	_
34-27	5343-5349	linear	_
34-28	5350-5360	regression	_
34-29	5361-5362	.	_

35-1	5363-5364	A	_
35-2	5365-5371	median	_
35-3	5372-5377	split	_
35-4	5378-5380	of	_
35-5	5381-5389	adjusted	_
35-6	5390-5394	TADS	_
35-7	5395-5401	scores	_
35-8	5402-5405	was	_
35-9	5406-5410	used	_
35-10	5411-5413	to	_
35-11	5414-5420	create	_
35-12	5421-5422	“	_
35-13	5423-5427	high	_
35-14	5428-5429	”	_
35-15	5430-5433	and	_
35-16	5434-5435	“	_
35-17	5436-5439	low	_
35-18	5440-5441	”	_
35-19	5442-5451	adversity	_
35-20	5452-5458	groups	_
35-21	5459-5461	in	_
35-22	5462-5466	both	_
35-23	5467-5474	samples	_
35-24	5475-5476	.	_

36-1	5477-5489	Neuroimaging	_
36-2	5490-5494	Data	_
36-3	5495-5503	Detailed	_
36-4	5504-5516	descriptions	_
36-5	5517-5525	relating	_
36-6	5526-5528	to	_
36-7	5529-5532	the	_
36-8	5533-5545	neuroimaging	_
36-9	5546-5556	parameters	_
36-10	5557-5560	and	_
36-11	5561-5574	preprocessing	_
36-12	5575-5578	are	_
36-13	5579-5587	provided	_
36-14	5588-5590	in	_
36-15	5591-5594	the	_
36-16	5595-5608	supplementary	_
36-17	5609-5617	material	_
36-18	5618-5619	.	_

37-1	5620-5629	Face-task	_
37-2	5630-5634	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
37-3	5635-5639	data	_
37-4	5640-5644	were	_
37-5	5645-5654	available	_
37-6	5655-5659	only	_
37-7	5660-5662	in	_
37-8	5663-5666	the	_
37-9	5667-5676	discovery	_
37-10	5677-5683	sample	_
37-11	5684-5685	.	_

38-1	5686-5697	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-2	5698-5701	MRI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-3	5702-5707	scans	_
38-4	5708-5712	were	_
38-5	5713-5722	available	_
38-6	5723-5725	in	_
38-7	5726-5730	both	_
38-8	5731-5734	the	_
38-9	5735-5744	discovery	_
38-10	5745-5748	and	_
38-11	5749-5752	the	_
38-12	5753-5764	replication	_
38-13	5765-5772	samples	_
38-14	5773-5774	.	_

39-1	5775-5787	Neuroimaging	_
39-2	5788-5792	data	_
39-3	5793-5797	were	_
39-4	5798-5806	analyzed	_
39-5	5807-5811	with	_
39-6	5812-5817	FMRIB	_
39-7	5818-5826	Software	_
39-8	5827-5834	Library	_
39-9	5835-5836	(	_
39-10	5837-5840	FSL	_
39-11	5841-5842	)	_
39-12	5843-5846	and	_
39-13	5847-5855	Analysis	_
39-14	5856-5858	of	_
39-15	5859-5869	Functional	_
39-16	5870-5881	NeuroImages	_
39-17	5882-5883	(	_
39-18	5884-5888	AFNI	_
39-19	5889-5890	)	_
39-20	5891-5896	using	_
39-21	5897-5900	the	_
39-22	5901-5909	standard	_
39-23	5910-5918	pipeline	_
39-24	5919-5923	that	_
39-25	5924-5932	included	_
39-26	5933-5938	brain	_
39-27	5939-5949	extraction	_
39-28	5950-5951	,	_
39-29	5952-5958	motion	_
39-30	5959-5969	correction	_
39-31	5970-5971	,	_
39-32	5972-5979	spatial	_
39-33	5980-5989	smoothing	_
39-34	5990-5991	,	_
39-35	5992-6004	prewhitening	_
39-36	6005-6006	,	_
39-37	6007-6016	high-pass	_
39-38	6017-6026	filtering	_
39-39	6027-6028	,	_
39-40	6029-6032	and	_
39-41	6033-6042	nonlinear	_
39-42	6043-6056	normalization	_
39-43	6057-6059	to	_
39-44	6060-6063	the	_
39-45	6064-6072	standard	_
39-46	6073-6080	MNI-152	_
39-47	6081-6089	template	_
39-48	6090-6091	(	_
39-49	6092-6101	described	_
39-50	6102-6104	in	_
39-51	6105-6111	detail	_
39-52	6112-6114	in	_
39-53	6115-6118	the	_
39-54	6119-6132	supplementary	_
39-55	6133-6141	material	_
39-56	6142-6143	)	_
39-57	6144-6145	.	_

40-1	6146-6155	Face-Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
40-2	6156-6160	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
40-3	6161-6163	We	_
40-4	6164-6173	conducted	_
40-5	6174-6178	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
40-6	6179-6184	while	_
40-7	6185-6197	participants	_
40-8	6198-6204	viewed	_
40-9	6205-6206	4	_
40-10	6207-6213	blocks	_
40-11	6214-6216	of	_
40-12	6217-6222	video	_
40-13	6223-6228	clips	_
40-14	6229-6231	of	_
40-15	6232-6237	happy	_
40-16	6238-6241	and	_
40-17	6242-6243	4	_
40-18	6244-6250	blocks	_
40-19	6251-6253	of	_
40-20	6254-6259	video	_
40-21	6260-6265	clips	_
40-22	6266-6268	of	_
40-23	6269-6276	fearful	_
40-24	6277-6283	facial	_
40-25	6284-6295	expressions	_
40-26	6296-6305	presented	_
40-27	6306-6308	in	_
40-28	6309-6321	pseudorandom	_
40-29	6322-6327	order	_
40-30	6328-6337	separated	_
40-31	6338-6340	by	_
40-32	6341-6347	blocks	_
40-33	6348-6350	of	_
40-34	6351-6352	a	_
40-35	6353-6360	dynamic	_
40-36	6361-6367	mosaic	_
40-37	6368-6376	baseline	_
40-38	6377-6378	(	_
40-39	6379-6386	control	_
40-40	6387-6395	stimulus	_
40-41	6396-6397	)	_
40-42	6398-6399	.	_

41-1	6400-6403	The	_
41-2	6404-6412	baseline	_
41-3	6413-6421	stimulus	_
41-4	6422-6425	was	_
41-5	6426-6435	generated	_
41-6	6436-6440	from	_
41-7	6441-6444	the	_
41-8	6445-6451	mosaic	_
41-9	6452-6458	images	_
41-10	6459-6461	of	_
41-11	6462-6465	the	_
41-12	6466-6472	facial	_
41-13	6473-6484	expressions	_
41-14	6485-6487	in	_
41-15	6488-6491	the	_
41-16	6492-6497	happy	_
41-17	6498-6501	and	_
41-18	6502-6509	fearful	_
41-19	6510-6516	blocks	_
41-20	6517-6518	.	_

42-1	6519-6525	Blocks	_
42-2	6526-6528	of	_
42-3	6529-6534	happy	_
42-4	6535-6538	and	_
42-5	6539-6546	fearful	_
42-6	6547-6553	facial	_
42-7	6554-6565	expressions	_
42-8	6566-6575	consisted	_
42-9	6576-6578	of	_
42-10	6579-6581	12	_
42-11	6582-6583	×	_
42-12	6584-6594	2.5-second	_
42-13	6595-6602	dynamic	_
42-14	6603-6608	video	_
42-15	6609-6614	clips	_
42-16	6615-6622	showing	_
42-17	6623-6624	a	_
42-18	6625-6632	neutral	_
42-19	6633-6639	facial	_
42-20	6640-6650	expression	_
42-21	6651-6659	changing	_
42-22	6660-6664	into	_
42-23	6665-6666	a	_
42-24	6667-6680	happy/fearful	_
42-25	6681-6691	expression	_
42-26	6692-6693	(	_
42-27	6694-6700	figure	_
42-28	6701-6702	1	_
42-29	6703-6704	)	_
42-30	6705-6706	.	_

43-1	6707-6710	The	_
43-2	6711-6716	total	_
43-3	6717-6725	duration	_
43-4	6726-6728	of	_
43-5	6729-6733	each	_
43-6	6734-6739	block	_
43-7	6740-6741	(	_
43-8	6742-6748	facial	_
43-9	6749-6760	expressions	_
43-10	6761-6764	and	_
43-11	6765-6772	dynamic	_
43-12	6773-6779	mosaic	_
43-13	6780-6781	)	_
43-14	6782-6785	was	_
43-15	6786-6788	30	_
43-16	6789-6796	seconds	_
43-17	6797-6798	.	_

44-1	6799-6802	Six	_
44-2	6803-6812	different	_
44-3	6813-6819	people	_
44-4	6820-6821	,	_
44-5	6822-6826	each	_
44-6	6827-6832	shown	_
44-7	6833-6838	twice	_
44-8	6839-6840	,	_
44-9	6841-6850	performed	_
44-10	6851-6854	the	_
44-11	6855-6860	happy	_
44-12	6861-6867	facial	_
44-13	6868-6879	expressions	_
44-14	6880-6881	.	_

45-1	6882-6889	Fearful	_
45-2	6890-6896	facial	_
45-3	6897-6907	expression	_
45-4	6908-6914	blocks	_
45-5	6915-6924	consisted	_
45-6	6925-6927	of	_
45-7	6928-6934	facial	_
45-8	6935-6946	expressions	_
45-9	6947-6949	of	_
45-10	6950-6951	5	_
45-11	6952-6961	different	_
45-12	6962-6968	people	_
45-13	6969-6970	,	_
45-14	6971-6975	each	_
45-15	6976-6981	shown	_
45-16	6982-6983	2	_
45-17	6984-6986	or	_
45-18	6987-6988	3	_
45-19	6989-6994	times	_
45-20	6995-6996	.	_

46-1	6997-7000	The	_
46-2	7001-7006	whole	_
46-3	7007-7014	imaging	_
46-4	7015-7022	session	_
46-5	7023-7029	lasted	_
46-6	7030-7031	8	_
46-7	7032-7039	minutes	_
46-8	7040-7042	10	_
46-9	7043-7050	seconds	_
46-10	7051-7052	.	_

47-1	7053-7066	Interregional	_
47-2	7067-7078	Correlation	_
47-3	7079-7081	of	_
47-4	7082-7086	BOLD	_
47-5	7087-7090	and	_
47-6	7091-7095	Gray	_
47-7	7096-7102	Matter	_
47-8	7103-7109	Volume	_
47-9	7110-7112	in	_
47-10	7113-7116	the	_
47-11	7117-7132	Face-Processing	_
47-12	7133-7140	Network	_
47-13	7141-7143	We	_
47-14	7144-7148	used	_
47-15	7149-7153	ROIs	_
47-16	7154-7158	that	_
47-17	7159-7163	were	_
47-18	7164-7171	defined	_
47-19	7172-7174	in	_
47-20	7175-7178	the	_
47-21	7179-7185	IMAGEN	_
47-22	7186-7195	subsample	_
47-23	7196-7198	of	_
47-24	7199-7203	1110	_
47-25	7204-7215	adolescents	_
47-26	7216-7217	(	_
47-27	7218-7222	mean	_
47-28	7223-7226	age	_
47-29	7227-7228	=	_
47-30	7229-7231	14	_
47-31	7232-7237	years	_
47-32	7238-7239	)	_
47-33	7240-7241	.	_

48-1	7242-7243	A	_
48-2	7244-7249	total	_
48-3	7250-7252	of	_
48-4	7253-7255	25	_
48-5	7256-7260	ROIs	_
48-6	7261-7269	relevant	_
48-7	7270-7273	for	_
48-8	7274-7278	face	_
48-9	7279-7289	processing	_
48-10	7290-7294	were	_
48-11	7295-7305	identified	_
48-12	7306-7311	using	_
48-13	7312-7313	a	_
48-14	7314-7327	probabilistic	_
48-15	7328-7331	map	_
48-16	7332-7334	as	_
48-17	7335-7344	described	_
48-18	7345-7347	in	_
48-19	7348-7354	detail	_
48-20	7355-7364	elsewhere	_
48-21	7365-7366	.	_

49-1	7367-7370	Our	_
49-2	7371-7379	previous	_
49-3	7380-7385	study	_
49-4	7386-7392	showed	_
49-5	7393-7397	that	_
49-6	7398-7403	these	_
49-7	7404-7408	ROIs	_
49-8	7409-7415	highly	_
49-9	7416-7423	overlap	_
49-10	7424-7428	with	_
49-11	7429-7433	BOLD	_
49-12	7434-7442	response	_
49-13	7443-7445	to	_
49-14	7446-7451	faces	_
49-15	7452-7454	in	_
49-16	7455-7458	the	_
49-17	7459-7463	NFBC	_
49-18	7464-7468	1986	_
49-19	7469-7475	sample	_
49-20	7476-7477	.	_

50-1	7478-7481	The	_
50-2	7482-7486	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
50-3	7487-7491	data	_
50-4	7492-7496	were	_
50-5	7497-7505	analyzed	_
50-6	7506-7508	as	_
50-7	7509-7516	follows	_
50-8	7517-7518	(	_
50-9	7519-7525	figure	_
50-10	7526-7527	2	_
50-11	7528-7529	)	_
50-12	7530-7531	.	_

51-1	7532-7535	For	_
51-2	7536-7540	each	_
51-3	7541-7551	individual	_
51-4	7552-7555	and	_
51-5	7556-7560	each	_
51-6	7561-7564	ROI	_
51-7	7565-7566	,	_
51-8	7567-7570	the	_
51-9	7571-7575	mean	_
51-10	7576-7580	BOLD	_
51-11	7581-7587	signal	_
51-12	7588-7592	time	_
51-13	7593-7599	series	_
51-14	7600-7603	was	_
51-15	7604-7614	calculated	_
51-16	7615-7617	by	_
51-17	7618-7627	averaging	_
51-18	7628-7631	the	_
51-19	7632-7636	BOLD	_
51-20	7637-7643	signal	_
51-21	7644-7648	from	_
51-22	7649-7652	all	_
51-23	7653-7659	voxels	_
51-24	7660-7672	constituting	_
51-25	7673-7676	the	_
51-26	7677-7680	ROI	_
51-27	7681-7683	at	_
51-28	7684-7689	every	_
51-29	7690-7694	time	_
51-30	7695-7700	point	_
51-31	7701-7702	(	_
51-32	7703-7706	150	_
51-33	7707-7709	in	_
51-34	7710-7715	total	_
51-35	7716-7717	)	_
51-36	7718-7719	.	_

52-1	7720-7723	The	_
52-2	7724-7728	BOLD	_
52-3	7729-7733	time	_
52-4	7734-7740	series	_
52-5	7741-7744	for	_
52-6	7745-7749	each	_
52-7	7750-7754	face	_
52-8	7755-7764	condition	_
52-9	7765-7768	was	_
52-10	7769-7777	realized	_
52-11	7778-7780	by	_
52-12	7781-7794	concatenating	_
52-13	7795-7798	the	_
52-14	7799-7803	BOLD	_
52-15	7804-7810	signal	_
52-16	7811-7815	from	_
52-17	7816-7819	the	_
52-18	7820-7833	corresponding	_
52-19	7834-7840	blocks	_
52-20	7841-7842	.	_

53-1	7843-7851	Nuisance	_
53-2	7852-7862	covariates	_
53-3	7863-7872	including	_
53-4	7873-7878	white	_
53-5	7879-7885	matter	_
53-6	7886-7893	signals	_
53-7	7894-7895	,	_
53-8	7896-7899	and	_
53-9	7900-7913	cerebrospinal	_
53-10	7914-7919	fluid	_
53-11	7920-7927	signals	_
53-12	7928-7929	,	_
53-13	7930-7933	and	_
53-14	7934-7935	6	_
53-15	7936-7942	motion	_
53-16	7943-7953	parameters	_
53-17	7954-7958	were	_
53-18	7959-7968	regressed	_
53-19	7969-7972	out	_
53-20	7973-7977	from	_
53-21	7978-7981	the	_
53-22	7982-7986	BOLD	_
53-23	7987-7994	signals	_
53-24	7995-7996	.	_

54-1	7997-8000	For	_
54-2	8001-8005	each	_
54-3	8006-8011	group	_
54-4	8012-8013	,	_
54-5	8014-8016	we	_
54-6	8017-8021	then	_
54-7	8022-8029	created	_
54-8	8030-8034	mean	_
54-9	8035-8037	25	_
54-10	8038-8039	×	_
54-11	8040-8042	25	_
54-12	8043-8054	correlation	_
54-13	8055-8063	matrices	_
54-14	8064-8067	for	_
54-15	8068-8071	the	_
54-16	8072-8076	BOLD	_
54-17	8077-8083	signal	_
54-18	8084-8086	by	_
54-19	8087-8096	averaging	_
54-20	8097-8104	Pearson	_
54-21	8105-8116	correlation	_
54-22	8117-8129	coefficients	_
54-23	8130-8137	between	_
54-24	8138-8142	each	_
54-25	8143-8147	pair	_
54-26	8148-8150	of	_
54-27	8151-8155	ROIs	_
54-28	8156-8157	.	_

55-1	8158-8163	Group	_
55-2	8164-8175	comparisons	_
55-3	8176-8178	of	_
55-4	8179-8183	fMRI	_
55-5	8184-8188	data	_
55-6	8189-8193	were	_
55-7	8194-8203	conducted	_
55-8	8204-8209	using	_
55-9	8210-8215	these	_
55-10	8216-8223	average	_
55-11	8224-8235	correlation	_
55-12	8236-8244	matrices	_
55-13	8245-8246	.	_

56-1	8247-8257	Structural	_
56-2	8258-8262	data	_
56-3	8263-8267	were	_
56-4	8268-8276	analyzed	_
56-5	8277-8279	as	_
56-6	8280-8287	follows	_
56-7	8288-8289	(	_
56-8	8290-8296	figure	_
56-9	8297-8298	2	_
56-10	8299-8300	)	_
56-11	8301-8302	.	_

57-1	8303-8314	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
57-2	8315-8318	MRI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
57-3	8319-8324	scans	_
57-4	8325-8329	were	_
57-5	8330-8334	used	_
57-6	8335-8337	to	_
57-7	8338-8345	measure	_
57-8	8346-8354	regional	_
57-9	8355-8359	gray	_
57-10	8360-8366	matter	_
57-11	8367-8373	volume	_
57-12	8374-8377	and	_
57-13	8378-8382	were	_
57-14	8383-8392	processed	_
57-15	8393-8398	using	_
57-16	8399-8402	FSL	_
57-17	8403-8404	’	_
57-18	8405-8406	s	_
57-19	8407-8416	optimized	_
57-20	8417-8428	voxel-based	_
57-21	8429-8440	morphometry	_
57-22	8441-8449	pipeline	_
57-23	8450-8451	.	_

58-1	8452-8456	From	_
58-2	8457-8461	each	_
58-3	8462-8464	of	_
58-4	8465-8468	the	_
58-5	8469-8471	25	_
58-6	8472-8476	ROIs	_
58-7	8477-8478	,	_
58-8	8479-8481	we	_
58-9	8482-8491	extracted	_
58-10	8492-8495	the	_
58-11	8496-8500	gray	_
58-12	8501-8507	matter	_
58-13	8508-8514	volume	_
58-14	8515-8518	for	_
58-15	8519-8523	each	_
58-16	8524-8535	participant	_
58-17	8536-8537	.	_

59-1	8538-8541	For	_
59-2	8542-8546	each	_
59-3	8547-8552	group	_
59-4	8553-8554	,	_
59-5	8555-8557	we	_
59-6	8558-8565	created	_
59-7	8566-8568	25	_
59-8	8569-8570	×	_
59-9	8571-8573	25	_
59-10	8574-8585	correlation	_
59-11	8586-8594	matrices	_
59-12	8595-8597	of	_
59-13	8598-8602	gray	_
59-14	8603-8609	matter	_
59-15	8610-8614	data	_
59-16	8615-8617	by	_
59-17	8618-8629	correlating	_
59-18	8630-8642	participants	_
59-19	8643-8644	’	_
59-20	8645-8649	gray	_
59-21	8650-8656	matter	_
59-22	8657-8663	volume	_
59-23	8664-8670	across	_
59-24	8671-8674	the	_
59-25	8675-8677	25	_
59-26	8678-8682	ROIs	_
59-27	8683-8684	.	_

60-1	8685-8690	Group	_
60-2	8691-8702	comparisons	_
60-3	8703-8707	were	_
60-4	8708-8717	conducted	_
60-5	8718-8723	using	_
60-6	8724-8729	these	_
60-7	8730-8737	average	_
60-8	8738-8749	correlation	_
60-9	8750-8758	matrices	_
60-10	8759-8761	of	_
60-11	8762-8775	interregional	_
60-12	8776-8780	gray	_
60-13	8781-8787	matter	_
60-14	8788-8794	volume	_
60-15	8795-8796	.	_

61-1	8797-8808	Statistical	_
61-2	8809-8817	Analyses	_
61-3	8818-8821	For	_
61-4	8822-8833	statistical	_
61-5	8834-8842	analyses	_
61-6	8843-8844	,	_
61-7	8845-8847	we	_
61-8	8848-8852	used	_
61-9	8853-8854	R	_
61-10	8855-8856	(	_
61-11	8857-8861	http	_
61-12	8862-8863	:	_
61-13	8864-8884	//cran.r-project.org	_
61-14	8885-8886	)	_
61-15	8887-8888	,	_
61-16	8889-8896	version	_
61-17	8897-8902	3.4.0	_
61-18	8903-8904	.	_

62-1	8905-8909	Data	_
62-2	8910-8914	were	_
62-3	8915-8923	visually	_
62-4	8924-8933	inspected	_
62-5	8934-8936	to	_
62-6	8937-8942	check	_
62-7	8943-8946	for	_
62-8	8947-8956	normality	_
62-9	8957-8958	.	_

63-1	8959-8961	If	_
63-2	8962-8971	necessary	_
63-3	8972-8973	,	_
63-4	8974-8976	we	_
63-5	8977-8981	used	_
63-6	8982-8989	Box–Cox	_
63-7	8990-8995	power	_
63-8	8996-9010	transformation	_
63-9	9011-9013	on	_
63-10	9014-9017	the	_
63-11	9018-9022	data	_
63-12	9023-9025	to	_
63-13	9026-9033	fulfill	_
63-14	9034-9037	the	_
63-15	9038-9047	normality	_
63-16	9048-9056	criteria	_
63-17	9057-9058	.	_

64-1	9059-9064	ANOVA	_
64-2	9065-9066	,	_
64-3	9067-9073	linear	_
64-4	9074-9084	regression	_
64-5	9085-9086	,	_
64-6	9087-9093	linear	_
64-7	9094-9099	mixed	_
64-8	9100-9105	model	_
64-9	9106-9107	,	_
64-10	9108-9116	logistic	_
64-11	9117-9127	regression	_
64-12	9128-9129	,	_
64-13	9130-9137	Pearson	_
64-14	9138-9149	correlation	_
64-15	9150-9151	,	_
64-16	9152-9155	and	_
64-17	9156-9157	t	_
64-18	9158-9163	tests	_
64-19	9164-9168	were	_
64-20	9169-9173	used	_
64-21	9174-9176	as	_
64-22	9177-9186	specified	_
64-23	9187-9189	in	_
64-24	9190-9191	“	_
64-25	9192-9199	Results	_
64-26	9200-9201	”	_
64-27	9202-9209	section	_
64-28	9210-9211	.	_

65-1	9212-9219	Results	_
65-2	9220-9223	are	_
65-3	9224-9234	visualized	_
65-4	9235-9239	with	_
65-5	9240-9248	BrainNet	_
65-6	9249-9255	Viewer	_
65-7	9256-9257	,	_
65-8	9258-9264	gplots	_
65-9	9265-9266	,	_
65-10	9267-9270	and	_
65-11	9271-9274	the	_
65-12	9275-9285	pirateplot	_
65-13	9286-9287	.	_

66-1	9288-9291	The	_
66-2	9292-9305	interregional	_
66-3	9306-9317	correlation	_
66-4	9318-9330	coefficients	_
66-5	9331-9335	were	_
66-6	9336-9345	estimated	_
66-7	9346-9348	in	_
66-8	9349-9352	the	_
66-9	9353-9357	each	_
66-10	9358-9364	groups	_
66-11	9365-9366	’	_
66-12	9367-9374	average	_
66-13	9375-9386	correlation	_
66-14	9387-9395	matrices	_
66-15	9396-9397	.	_

67-1	9398-9402	Note	_
67-2	9403-9404	,	_
67-3	9405-9414	therefore	_
67-4	9415-9416	,	_
67-5	9417-9421	that	_
67-6	9422-9424	we	_
67-7	9425-9434	conducted	_
67-8	9435-9438	the	_
67-9	9439-9448	following	_
67-10	9449-9454	group	_
67-11	9455-9466	comparisons	_
67-12	9467-9469	at	_
67-13	9470-9473	the	_
67-14	9474-9479	level	_
67-15	9480-9482	of	_
67-16	9483-9490	average	_
67-17	9491-9502	correlation	_
67-18	9503-9515	coefficients	_
67-19	9516-9518	of	_
67-20	9519-9523	each	_
67-21	9524-9529	group	_
67-22	9530-9531	.	_

68-1	9532-9535	The	_
68-2	9536-9541	group	_
68-3	9542-9553	comparisons	_
68-4	9554-9558	were	_
68-5	9559-9566	carried	_
68-6	9567-9570	out	_
68-7	9571-9581	separately	_
68-8	9582-9585	for	_
68-9	9586-9590	BOLD	_
68-10	9591-9597	signal	_
68-11	9598-9599	(	_
68-12	9600-9609	discovery	_
68-13	9610-9616	sample	_
68-14	9617-9618	)	_
68-15	9619-9622	and	_
68-16	9623-9627	gray	_
68-17	9628-9634	matter	_
68-18	9635-9641	volume	_
68-19	9642-9646	data	_
68-20	9647-9648	(	_
68-21	9649-9658	discovery	_
68-22	9659-9662	and	_
68-23	9663-9674	replication	_
68-24	9675-9681	sample	_
68-25	9682-9683	)	_
68-26	9684-9685	.	_

69-1	9686-9697	Correlation	_
69-2	9698-9710	coefficients	_
69-3	9711-9713	in	_
69-4	9714-9718	each	_
69-5	9719-9725	groups	_
69-6	9726-9727	’	_
69-7	9728-9735	average	_
69-8	9736-9747	correlation	_
69-9	9748-9756	matrices	_
69-10	9757-9761	were	_
69-11	9762-9771	converted	_
69-12	9772-9776	with	_
69-13	9777-9783	Fisher	_
69-14	9784-9785	r	_
69-15	9786-9788	to	_
69-16	9789-9790	z	_
69-17	9791-9797	before	_
69-18	9798-9809	statistical	_
69-19	9810-9821	comparisons	_
69-20	9822-9823	.	_

70-1	9824-9826	To	_
70-2	9827-9834	analyze	_
70-3	9835-9838	the	_
70-4	9839-9850	PRS-related	_
70-5	9851-9862	differences	_
70-6	9863-9865	in	_
70-7	9866-9879	interregional	_
70-8	9880-9892	correlations	_
70-9	9893-9894	,	_
70-10	9895-9897	we	_
70-11	9898-9902	used	_
70-12	9903-9906	the	_
70-13	9907-9916	following	_
70-14	9917-9927	analytical	_
70-15	9928-9936	strategy	_
70-16	9937-9938	.	_

71-1	9939-9944	First	_
71-2	9945-9946	,	_
71-3	9947-9949	we	_
71-4	9950-9958	compared	_
71-5	9959-9964	study	_
71-6	9965-9971	groups	_
71-7	9972-9975	for	_
71-8	9976-9979	the	_
71-9	9980-9984	mean	_
71-10	9985-9987	of	_
71-11	9988-9991	300	_
71-12	9992-10001	pair-wise	_
71-13	10002-10013	correlation	_
71-14	10014-10026	coefficients	_
71-15	10027-10028	(	_
71-16	10029-10037	obtained	_
71-17	10038-10042	from	_
71-18	10043-10047	each	_
71-19	10048-10054	groups	_
71-20	10055-10056	’	_
71-21	10057-10064	average	_
71-22	10065-10076	correlation	_
71-23	10077-10085	matrices	_
71-24	10086-10087	)	_
71-25	10088-10093	using	_
71-26	10094-10102	unpaired	_
71-27	10103-10104	t	_
71-28	10105-10109	test	_
71-29	10110-10111	.	_

72-1	10112-10123	Statistical	_
72-2	10124-10136	significance	_
72-3	10137-10140	was	_
72-4	10141-10151	considered	_
72-5	10152-10154	at	_
72-6	10155-10156	P	_
72-7	10157-10162	value	_
72-8	10163-10165	of	_
72-9	10166-10167	<	_
72-10	10168-10171	.05	_
72-11	10172-10174	as	_
72-12	10175-10177	we	_
72-13	10178-10182	test	_
72-14	10183-10187	here	_
72-15	10188-10191	the	_
72-16	10192-10199	average	_
72-17	10200-10202	of	_
72-18	10203-10206	all	_
72-19	10207-10210	the	_
72-20	10211-10224	interregional	_
72-21	10225-10236	correlation	_
72-22	10237-10249	coefficients	_
72-23	10250-10256	within	_
72-24	10257-10260	the	_
72-25	10261-10276	face-processing	_
72-26	10277-10284	network	_
72-27	10285-10286	.	_

73-1	10287-10293	Second	_
73-2	10294-10295	,	_
73-3	10296-10298	if	_
73-4	10299-10303	this	_
73-5	10304-10314	comparison	_
73-6	10315-10318	was	_
73-7	10319-10330	significant	_
73-8	10331-10332	,	_
73-9	10333-10335	we	_
73-10	10336-10344	compared	_
73-11	10345-10350	study	_
73-12	10351-10357	groups	_
73-13	10358-10359	’	_
73-14	10360-10367	average	_
73-15	10368-10379	correlation	_
73-16	10380-10388	matrices	_
73-17	10389-10392	for	_
73-18	10393-10396	the	_
73-19	10397-10401	mean	_
73-20	10402-10413	correlation	_
73-21	10414-10426	coefficients	_
73-22	10427-10428	:	_
73-23	10429-10430	(	_
73-24	10431-10432	1	_
73-25	10433-10434	)	_
73-26	10435-10442	between	_
73-27	10443-10446	the	_
73-28	10447-10451	core	_
73-29	10452-10455	and	_
73-30	10456-10459	the	_
73-31	10460-10465	other	_
73-32	10466-10481	face-processing	_
73-33	10482-10489	regions	_
73-34	10490-10491	(	_
73-35	10492-10496	mean	_
73-36	10497-10499	of	_
73-37	10500-10503	114	_
73-38	10504-10513	pair-wise	_
73-39	10514-10526	correlations	_
73-40	10527-10528	)	_
73-41	10529-10532	and	_
73-42	10533-10534	(	_
73-43	10535-10536	2	_
73-44	10537-10538	)	_
73-45	10539-10545	within	_
73-46	10546-10549	the	_
73-47	10550-10554	core	_
73-48	10555-10562	regions	_
73-49	10563-10565	of	_
73-50	10566-10570	face	_
73-51	10571-10581	processing	_
73-52	10582-10583	(	_
73-53	10584-10588	mean	_
73-54	10589-10591	of	_
73-55	10592-10594	15	_
73-56	10595-10604	pair-wise	_
73-57	10605-10617	correlations	_
73-58	10618-10619	)	_
73-59	10620-10621	.	_

74-1	10622-10624	We	_
74-2	10625-10632	defined	_
74-3	10633-10636	the	_
74-4	10637-10641	core	_
74-5	10642-10648	system	_
74-6	10649-10651	to	_
74-7	10652-10659	include	_
74-8	10660-10663	the	_
74-9	10664-10671	lateral	_
74-10	10672-10681	occipital	_
74-11	10682-10688	cortex	_
74-12	10689-10690	,	_
74-13	10691-10700	posterior	_
74-14	10701-10704	STS	_
74-15	10705-10706	,	_
74-16	10707-10710	and	_
74-17	10711-10714	FFA	_
74-18	10715-10716	(	_
74-19	10717-10723	figure	_
74-20	10724-10725	2	_
74-21	10726-10727	)	_
74-22	10728-10729	.	_

